<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162743</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG2I0021</org_study_id>
    <nct_id>NCT04162743</nct_id>
  </id_info>
  <brief_title>The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression</brief_title>
  <official_title>The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that trazodone does not worse nocturnal oxygen saturation in
      insomnic ischemic stroke patients with obstructive sleep apnea (OSA) and depression and has
      beneficial effect in selected stroke patients with low arousal threshold phenotype OSA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nocturnal oxygen saturation</measure>
    <time_frame>the polysomnography study night before take drug</time_frame>
    <description>mean and minimum oxyhemoglobin saturation (%) detected by pulse oximetry during polysomnography study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep apnea severity index</measure>
    <time_frame>the polysomnography study night before take drug</time_frame>
    <description>apnea-hypopnea index, desaturation index according to The American Academy of Sleep Medicine (AASM) scoring manual version 2.0.3: Obstructive apnea: no airflow &gt;= 10 s with respiratory effort (per hour of time); central apnea: no airflow without respiratory effort (per hour of time). Hypopnea: airflow decrease &gt;30% lasting &gt;= 10 s, followed by either oxygen desaturation &gt; 3% or EEG arousal (per hour of time). The desaturation index: number of desaturations per hour of time.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>take trazodone 100mg hs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>take placebo pill hs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>take trazodone 100mg before polysomnography</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>take placebo oral tablet before polysomnography</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insomnic ischemic stroke patients with OSA and depression.

        Exclusion Criteria:

          -  unclear consciousness, unstable vital sign or neurologic sign, unstable medical
             conditions such as delirium, active infection, evidence of overt congestive cardiac
             failure, liver dysfunction with ascites, thyroid disease, end-stage-renal-disease
             receiving dialysis.

          -  overnight mean oxygen saturation (SaO2) nadir is â‰¤ 70% at baseline

          -  take monoamine oxidase inhibitors (MAOI), any medication that may affect breathing,
             sleep, or muscle activity

          -  any known allergy to trazodone

          -  sleep disorder other than OSA (e.g., periodic leg movement syndrome, restless legs
             syndrome, central sleep apnea/Cheyne-Stokes respiration).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Keelung</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>CHEN,CHUNG YAO</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

